Actively Recruiting
Evaluation of BMS-986470s Safety and Early Effects in Adults with Sickle Cell Disease and Healthy Volunteers Using a Randomized Placebo-Controlled Design
Led by Bristol-Myers Squibb · Updated on 2026-08-18
224
Participants Needed
32
Research Sites
44 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying BMS-986470 to assess its safety, tolerability, how the body processes it, and its early effects in both healthy volunteers and people with sickle cell disease. The study also examines how food and stomach pH levels might affect the drug. This phase 12a trial is randomized, double-blinded, and placebo-controlled to evaluate these aspects comprehensively. Participants will receive BMS-986470 or placebo at specified doses on designated days. Additional drugs like famotidine and pantoprazole are also given at certain times to study their effects. The study has multiple cohorts including healthy adults and patients with sickle cell disease with specific genotypes and vaso-occlusive crisis histories. Throughout the study, participants will be closely monitored for adverse events, blood markers including fetal hemoglobin levels, and other laboratory measurements for up to 26 months. Safety, pharmacokinetics, and preliminary efficacy outcomes are tracked with regular assessments and blood tests. The total study duration allows for detailed evaluation of how the drug affects participants over time.
CONDITIONS
Brief Title
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here